Protea Biosciences Group Inc (PRGBQ)

OTC Markets
0.010
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    0.010 - 0.010

PRGBQ Overview

Prev. Close
0.01
Day's Range
0.01-0.01
Revenue
-
Open
0.01
52 wk Range
-
EPS
-7.22
Volume
0
Market Cap
79.41K
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,129
P/E Ratio
-
Beta
-
1-Year Change
0%
Shares Outstanding
7,941,326
Next Earnings Date
Sep 01, 2021
What is your sentiment on Protea Biosciences Group Inc?
or
Market is currently closed. Voting is open during market hours.

Protea Biosciences Group Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary

Protea Biosciences Group Inc Company Profile

Protea Biosciences Group Inc Company Profile

Employees
25

Protea Biosciences Group, Inc., a molecular information company, provides proprietary, bioanalytical workflows to the pharmaceutical and life science industries. It develops Histology Guided Mass Spec Imaging, a software suite that allows researchers to share, annotate, and direct the analysis of specific tissue morphologies and cell subpopulations by mass spec imaging; and prototype instrumentation of LAESI technology that integrates with laboratory instruments. The company also develops technology to improve the molecular characterization of biotherapeutics; and bioanalytical reagents and products to facilitate sample preparation prior to mass spectrometry analysis. In addition, it offers bioanalytical services that enable the identification and characterization of small and large molecules; and integrated proteomics, metabolomics, protein characterization, and mass spec imaging bioanalytical services. Further, the company has a collaborative research and license agreement with The Yale University School of Medicine to differentiate benign melanocytic nevi from malignant melanoma; a collaborative research agreement with the Memorial Sloan-Kettering Cancer Center and the Dana-Farber Cancer Institute to improve the analysis of early stage lung adenocarcinoma; and a collaboration with Protein Metrics Inc. for further applications development of the analytical software for Protea’s bioanalytical services. It also has an agreement with MatTek Corporation that allows the company to include MatTek’s human cell based in vitro tissue models with its molecular imaging services. The company serves pharmaceutical, chemical and biotechnology companies, and academic and government laboratories worldwide. Protea Biosciences Group was founded in 2001 and is based in Morgantown, West Virginia. On December 1, 2017, Protea Biosciences Group, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of West Virginia.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.